| Aug 7 2024 |
APHIS Announces Flexibility Allowing for Reuse of BRS Import Labels |
Keller and Heckman LLP |
| Aug 7 2024 |
Cal/OSHA and the Agriculture Industry: Compliance Challenges and Practice Pointers [Podcast] |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Aug 7 2024 |
Florida Division of Alcoholic Beverages and Tobacco Announces 2024 Quota Beverage License Drawing Entry Period |
Jones Walker LLP |
| Aug 6 2024 |
Madam Policy: Jean Terranova, Senior Director of Policy and Research at Community Servings: Driving the Future of Nutrition & Food Security Policy [Podcast] |
Bracewell LLP |
| Aug 6 2024 |
Ohio Now Has Legal Recreational Marijuana: What Employers Need to Know |
Barnes & Thornburg LLP |
| Aug 6 2024 |
Unpacking Averages: Is It Too Soon to Study the Postmarket Experience of AI-Driven Medical Devices? |
Epstein Becker & Green, P.C. |
| Aug 6 2024 |
FDA to Hold Public Meeting on Post-Market Chemical Assessment |
Keller and Heckman LLP |
| Aug 5 2024 |
Medicare Part D Preemption: Supreme Court Review Uncertain |
Squire Patton Boggs (US) LLP |
| Aug 5 2024 |
Longevity Series: Dipping Our Toes in the Fountain of Youth: An Introduction into Longevity Research |
Womble Bond Dickinson (US) LLP |
| Aug 5 2024 |
Food & Chemicals Unpacked: Economic Adulteration: Secrets in the Sauce [Podcast] |
Keller and Heckman LLP |
| Aug 3 2024 |
FDA Gives Companies a New Way to Fight Misinformation |
McDermott Will & Schulte LLP |
| Aug 2 2024 |
Olive Oil Fraud and Mislabeling Cases in EU Hit Record High |
Keller and Heckman LLP |
| Aug 2 2024 |
Precision Lens Pays $12 Million to Resolve FCA and AKS Violations |
ArentFox Schiff LLP |
| Aug 2 2024 |
Beer and Liquor Lobbies Quarrel Over Tax Policies While Facing TCJA Sunset |
Jones Walker LLP |
| Aug 1 2024 |
Revolutionizing Cancer Treatment with Digital Pathology Predictions |
Foley & Lardner LLP |
| Aug 1 2024 |
2024 Mid-year Employment Law Updates |
Polsinelli PC |
| Aug 1 2024 |
Current Trends in Legislation – June & July 2024 |
CMBG3 Law |
| Aug 1 2024 |
FDA: The Effects of Loper on the Regulatory Agenda |
Foley & Lardner LLP |
| Aug 1 2024 |
Diagnosing Health Care Podcast: The DEA Is Knocking at Your Door . . . Are You Prepared? [Podcast] |
Epstein Becker & Green, P.C. |
| Aug 1 2024 |
Sponsor’s Role in Regulatory Testing — A Conversation with Lara Hall [Podcast] |
Bergeson & Campbell, P.C. |
| Jul 31 2024 |
PBM Policy and Legislative Update — Summer 2024 |
Mintz |
| Jul 31 2024 |
The Supreme Court of Justice Confirms Relevant Criteria Related to The Legal Standing to Claim the Invalidity of A Pharmaceutical Patent. |
OLIVARES |
| Jul 31 2024 |
NREL Releases Parts 1 and 2 of SAF State-of-Industry Report |
Bergeson & Campbell, P.C. |
| Jul 31 2024 |
This Week in 340B: July 23 – 29, 2024 |
McDermott Will & Schulte LLP |
| Jul 30 2024 |
2024 Agile BioFoundry Industry Day Will Be Held September 12, 2024 |
Bergeson & Campbell, P.C. |
| Jul 30 2024 |
2024 NIOSH Nanotechnology Health and Safety Summit Will Be Held October 9-10, 2024 |
Bergeson & Campbell, P.C. |
| Jul 30 2024 |
FDA’s Second Untitled Letter of the Year – An Apparently Tough Choice Between Raising Awareness and Public Safety for Anaphylaxis Drugs |
Sheppard, Mullin, Richter & Hampton LLP |
| Jul 30 2024 |
USDA Publishes Proposed Rule to Reduce Salmonella in Poultry Products |
Keller and Heckman LLP |
| Jul 30 2024 |
After Loper Bright, Should the FTC's Views on Advertising Interpretation Still Receive Deference? |
Katten |
| Jul 29 2024 |
Advancements in CAR-T Therapy Manufacturing Processes |
Foley & Lardner LLP |
| Jul 29 2024 |
Biotechnology Regulatory Services Will Hold Annual Stakeholder Meeting on November 14, 2024; Stakeholders Can Suggest Topics until September 13 |
Bergeson & Campbell, P.C. |
| Jul 29 2024 |
Challenges to LDT Final Rule Continue as Rule Goes into Effect |
Polsinelli PC |
| Jul 29 2024 |
FDA Guidance on DSCSA Small Dispenser Exemption and Exemptions and Waivers for Other Trading Partnersv |
Epstein Becker & Green, P.C. |
| Jul 29 2024 |
FDA Issues Guidance Intended to Diversify and Enhance Clinical Trial Participation |
Mintz |
| Jul 29 2024 |
HHS-OIG Highlights Anti-Fraud Safeguards Of Refund, Discount Program Offered By Pharma To Alleviate Drug's Cost |
Barnes & Thornburg LLP |
